Furthermore, prolactin (PRL) signalling, identified here through pathway analysis, is upregulated in numerous hormone-dependent cancers including ovarian, breast, prostate and endometrial cancer and is linked to cancer via activation of JAK/STAT, AKT and MAPK pathways [64–69]. The gene discussed is AKT1; the disease is endometrial cancer.